News articles about Spark Therapeutics (NASDAQ:ONCE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spark Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.461836843669 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Spark Therapeutics (NASDAQ:ONCE) opened at $54.80 on Wednesday. The firm has a market capitalization of $2,030.00, a PE ratio of -7.61 and a beta of 3.02. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $91.75.

A number of brokerages have issued reports on ONCE. Mizuho began coverage on Spark Therapeutics in a research note on Monday. They issued a “buy” rating and a $79.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $65.00 price target on shares of Spark Therapeutics in a research note on Thursday, February 8th. Sanford C. Bernstein set a $71.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, December 13th. Chardan Capital cut their price target on Spark Therapeutics from $100.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $105.00 price target on shares of Spark Therapeutics in a research note on Wednesday, January 24th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have assigned a buy rating to the company’s stock. Spark Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $73.73.

In other news, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the completion of the transaction, the insider now owns 215,000 shares in the company, valued at $15,333,800. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Stephen W. Webster sold 10,000 shares of Spark Therapeutics stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $70.14, for a total value of $701,400.00. Following the completion of the transaction, the chief financial officer now owns 12,500 shares of the company’s stock, valued at approximately $876,750. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,018 shares of company stock valued at $1,058,834. Company insiders own 7.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Spark Therapeutics (ONCE) Stock Price” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://theolympiareport.com/2018/02/14/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-spark-therapeutics-once-stock-price.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.